Effectiveness of lenalidomide in relapsed primary cutaneous diffuse large B‐cell lymphoma, leg type

Key Clinical Message The primary cutaneous diffuse large B‐cell lymphoma, leg type (PCDLBCL‐LT) has a poor prognosis. R‐CHOP with or without radiotherapy is the available recommendations for first‐line treatment. Relapses/refractory cases are frequent with no standardized therapeutic guidelines. Len...

Full description

Saved in:
Bibliographic Details
Published in:Clinical case reports 2019-05, Vol.7 (5), p.964-967
Main Authors: Al Dhafiri, Mahdi, Sicre de Fontbrune, Flore, Marinho, Eduardo, Deschamps, Lydia, Di‐Lucca, Julie, Crickx, Beatrice, Descamps, Vincent
Format: Article
Language:English
Subjects:
Age
Biopsy
Case Report
Case Reports
chemotherapy
Immunotherapy
leg type
lenalidomide
Lymphoma
Medical prognosis
Mutation
Neutropenia
primary cutaneous diffuse large B‐cell lymphoma
Radiation therapy
Targeted cancer therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Key Clinical Message The primary cutaneous diffuse large B‐cell lymphoma, leg type (PCDLBCL‐LT) has a poor prognosis. R‐CHOP with or without radiotherapy is the available recommendations for first‐line treatment. Relapses/refractory cases are frequent with no standardized therapeutic guidelines. Lenalidomide seems to be an excellent therapeutic option as a second‐line treatment of relapsed PCDLBCL‐LT. The primary cutaneous diffuse large B‐cell lymphoma, leg type (PCDLBCL‐LT) has a poor prognosis. R‐CHOP with or without radiotherapy is the available recommendations for first‐line treatment. Relapses/refractory cases are frequent with no standardized therapeutic guidelines. Lenalidomide seems to be an excellent therapeutic option as a second‐line treatment of relapsed PCDLBCL‐LT.
ISSN:2050-0904
2050-0904
DOI:10.1002/ccr3.2137